The value of osteoporosis interventions: evaluating the cost-effectiveness and incorporating patients’ preference

骨质疏松症(OP)是一种严重的疾病和经济负担。在澳大利亚，许多药物都是公开可用并得到补贴的，许多新药也即将问世。然而，在没有确凿的健康经济证据的情况下，它们的价值值得怀疑。此外，患者对OP治疗的偏好还不是很清楚。我的项目是开发一个全球卫生经济学模型，以确定具有成本效益的治疗方法，并吸引患者对不同的OP治疗方案的偏好。

Osteoporosis (OP) poses substantial disease and economic burden. Many medications are publicly available and subsidized in Australia, and many new medications are on the horizon. Their value for money, however, is questionable without solid health economic evidence. In addition, patient preference for OP treatment is not well understood. My project is to develop a global health economics model to identify cost-effective treatments, and to elicit patient preference for different OP treatments.